
Harnessing the predictive power of blood-based miRNAs
Company
Hummingbird is harnessing the predictive power of blood-borne miRNAs to provide insights into human health and disease. Analysis of miRNAs with Hummingbird’s platform holds the potential for early disease detection, disease-specific prognostics, treatment response prediction, and the development of patient-centric therapies.
The privately held company is based in Heidelberg, Germany.